Aristopharma Ltd. has launched Sabicard 50 mg, 100 mg & 200 mg tablets, which is the preparation of Sacubitril & Valsartan
Sacubitril/Valsartan, a new class of drug called Angiotensin Receptor Neprilysin Inhibitor (ARNI), is a US FDA-approved highly recommended treatment approach for patients with chronic heart failure. Here, Sacubitril is a neprilysin enzyme inhibitor that helps to maintain cardiovascular homeostasis and Valsartan reduces cardiac workload by reducing peripheral resistance, sodium & water retention in the body. Therefore, Sacubitril/Valsartan has transformed the treatment landscape of heart failure and widened the treatment horizon as an incredible drug of choice
FR
DE